Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)

Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months' follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.

Authors

Institutions

Publication Details

Journal
Acta Dermato Venereologica
Published
2024-11-27
DOI
https://doi.org/10.2340/actadv.v104.40946
Citations
2
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.48

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)

Lara Valeska Maul, Thomas M. Kündig, Elisabeth Victoria Goessinger, Raphael Micheroli et al.
2 citations
Acta Dermato Venereologica
Psoriasis: Treatment and Pathogenesis
0.48
article

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)

Lara Valeska Maul, Thomas M. Kündig, Elisabeth Victoria Goessinger, Raphael Micheroli, Melike Ak, Alexander A. Navarini, Martina Burlando, Simona Steinmann, Enric Mateu, Elisabeth Roider, Julia‐Tatjana Maul, Sara E. Cerminara, Georgios Kokolakis, Felix Oestereich, Anna Darzina, Iker Oyanguren Monferrer
article en
2 citations

Abstract

Real-world data on the effectiveness and safety of tildrakizumab, an interleukin 23p19 inhibitor, in Switzerland is limited. The objectives of this analysis were to assess the effectiveness and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis in Switzerland. Twenty-eight adults from the Swiss Dermatology Network for Targeted Therapies registry (SDNTT), who were on tildrakizumab treatment and had at least 3 months' follow-up, were enrolled in this prospective, multicentre study. No missing data imputation was performed. The median Psoriasis Area and Severity Index (PASI) decreased from 9.5 at baseline to 2.1 and 0.3 (both p < 0.001) after 3 and 18 months, respectively, of tildrakizumab treatment. After 3 months, 76.9%/30.8% patients reached an absolute PASI < 3/ < 1. These rates increased to 85.7%/57.1% after 18 months of treatment. The proportions of patients achieving PASI 90/100 responses were 47.8%/30.4% at month 6 and 42.9%/14.3% at month 18. A significant improvement in quality of life up to 18 months of follow-up was observed as measured by the Dermatology Life Quality Index. There were no treatment discontinuations due to adverse events. This real-world registry provides robust evidence supporting the long-term effectiveness and favourable safety profile of tildrakizumab in treating patients with moderate-to-severe psoriasis.

Acta Dermato VenereologicaVol. 104
University of Zurich (CH), University Hospital of Basel (CH), Humboldt-Universität zu Berlin (DE), Ecosens (Switzerland) (CH), University Hospital of Zurich (CH), Teulades i Façanes Multifuncionals (Spain) (ES), Ospedale Policlinico San Martino (IT), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
National Science Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, L'Oreal USA, Biogen, Celgene, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, MannKind Corporation, Allergy Therapeutics, Incyte, XBiotech, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Galderma, Basilea Pharmaceutica, LEO Pharma, Sanofi Genzyme, UCB Pharma, Actelion Pharmaceuticals, Cilag
Responsible consumption and production
Openalex Percentile: Top 33%
Psoriasis: Treatment and Pathogenesis
0.48
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.